Milan Nemy

Milan Nemy

Auto-generated profile, based on publicly available information

Milan Nemy

Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Blickagången 16, Huddinge 14183, Sweden; Department of Cognitive Systems and Neurosciences, Czech Institute of Informatics, Robotics and Cybernetics, Czech Technical University in Prague, Jugoslávských partyzánů 1580/3, Prague 160 00, Czech Republic

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2022 in Brain
Verified
Journal Article
Open access
PDF file
MNMilan Nemy
Milan Nemy
MDMartin Dyrba
Martin Dyrba
FBFrederic Brosseron
Frederic Brosseron
KBKatharina Buerger
Katharina Buerger
PDPeter Dechent
Peter Dechent
DFDaniel Ferreira
Daniel Ferreira
Previous studies have shown that the cholinergic nucleus basalis of Meynert and its white matter projections are affected in Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI). However, it is still unknown if these alterations can be found in individuals with subjective cognitive decline (SCD), and whether they are more pronounced than changes found in conventional brain volumetric measurements. To address these questions, we investigated microstructural alterations of two major cholinergic pathways in individuals along the AD continuum using an in vivo model of the human cholinergic system based on neuroimaging. We included 405 participants (53 AD, 66 MCI, 174 SCD, and 112 healthy controls) from the Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE) Longitudinal Cognitive Impairment and Dementia Study (DELCODE). We modelled the cholinergic white matter pathways with an enhanced diffusion neuroimaging pipeline that included probabilistic fiber-tracking methods and prior anatomical knowledge. The integrity of the cholinergic white matter pathways was compared between stages of the AD continuum, in the whole cohort and in a CSF amyloid-beta stratified subsample. The discriminative power of the integrity of the pathways was compared to the conventional volumetric measures of hippocampus and nucleus basalis of Meynert, using a receiver operating characteristics analysis. A multivariate model was employed to investigate the role of these pathways in relation to cognitive performance. We found that the integrity of the cholinergic white matter pathways was significantly reduced in all stages of the AD continuum, including individuals with SCD. The differences involved posterior cholinergic white matter in the SCD stage and extended to anterior frontal white matter in MCI and AD dementia stages. Both cholinergic pathways and conventional volumetric measures showed higher predictive power in the more advanced stages of the disease, i.e., MCI and AD dementia. In contrast, the integrity of cholinergic pathways was more informative in distinguishing SCD from healthy controls, as compared with the volumetric measures. The multivariate model revealed a moderate contribution of the cholinergic white matter pathways but not of volumetric measures towards memory tests in the SCD and MCI stages. In conclusion, we demonstrated that cholinergic white matter pathways are altered already in SCD individuals, preceding the more widespread alterations found in MCI and AD. The integrity of the cholinergic pathways identified the early stages of AD better than conventional volumetric measures such as hippocampal volume or volume of cholinergic nucleus basalis of Meynert.

21 June 2025 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Open access
JPJaroslav Pažout
Jaroslav Pažout
MNMilan Němý
Milan Němý
JMJakub Mikeš
Jakub Mikeš
JJJan Jirman
Jan Jirman
JKJan Kubr
Jan Kubr
FDFrantisek Duska
Frantisek Duska
Patient-ventilator asynchronies (PVA) are associated with ventilator-induced lung injury and increased mortality. Current detection methods rely on static thresholds, extensive preprocessing, or proprietary ventilator data. This study aimed to develop and validate a fully online, real-time system that detects and classifies PVAs directly from ventilator screen data while alerting clinicians based on severity. The SmartAlert system was developed using ventilator screen recordings from ICU patients. It extracts pressure and flow waveforms from video recordings, converts them into time-series data, and employs deep neural networks to classify asynchronies and assign alarm levels from no urgency to most urgent. A dataset of 381,280 double-breath units was independently annotated by two expert intensivists. Two deep learning models were trained: one for alarm prediction and another for asynchrony classification (ineffective triggering, double cycling, high inspiratory effort, no asynchrony). Performance was evaluated using accuracy, sensitivity, specificity, and AUC-ROC, compared to expert consensus. SmartAlert demonstrated strong performance for alarm level prediction (overall accuracy: 83.8 %, weighted AUC-ROC: 0.943 [95 % CI: 0.941-0.945]) and PVA classification (weighted accuracy: 89.3 %, weighted AUC-ROC: 0.951 [95 % CI: 0.950-0.953]). It showed high specificity for urgent alarms (99.9 % for level 3) and PVA types (98.5 % for ineffective triggering, 96.9 % for double cycling, 94.8 % for high inspiratory effort). We developed and internally validated SmartAlert, an automated system that detects PVAs, classifies severity, and alerts clinicians in real time. Its potential to reduce alarm fatigue, optimize ventilator settings, and improve patient outcomes remains to be tested in clinical trials.

20 December 2024 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
VSVojtěch Sedlák
Vojtěch Sedlák
MNMilan Němý
Milan Němý
MMMartin Májovský
Martin Májovský
ABAdéla Bubeníková
Adéla Bubeníková
LNLove Engstrom Nordin
Love Engstrom Nordin
DNDavid Netuka
David Netuka
BACKGROUND AND PURPOSE: Diffuse gliomas, a heterogeneous group of primary brain tumors, have traditionally been stratified by histology, but recent insights into their molecular features, especially the IDH mutation status, have fundamentally changed their classification and prognosis. Current diagnostic methods, still predominantly relying on invasive biopsy, necessitate the exploration of noninvasive imaging alternatives for glioma characterization. MATERIALS AND METHODS: In this prospective study, we investigated the utility of the spherical mean technique (SMT) in predicting the IDH status and histologic grade of adult-type diffuse gliomas. Patients with histologically confirmed adult-type diffuse glioma underwent a multiparametric MRI examination using a 3T system, which included a multishell diffusion sequence. Advanced diffusion parameters were obtained using SMT, diffusional kurtosis imaging, and ADC modeling. The diagnostic performance of studied parameters was evaluated by plotting receiver operating characteristic curves with associated area under curve, specificity, and sensitivity values. RESULTS: A total of 80 patients with a mean age of 48 (SD, 16) years were included in the study. SMT metrics, particularly microscopic fractional anisotropy (μFA), intraneurite voxel fraction, and μFA to the third power (μFA3), demonstrated strong diagnostic performance (all AUC = 0.905, 95% CI, 0.835–0.976; P < .001) in determining IDH status and compared favorably with diffusional kurtosis imaging and ADC models. These parameters also showed a strong predictive capability for tumor grade, with intraneurite voxel fraction and μFA achieving the highest diagnostic accuracy (AUC = 0.937, 95% CI, 0.880–0.993; P < .001). Control analyses on normal-appearing brain tissue confirmed the specificity of these metrics for tumor tissue. CONCLUSIONS: Our study highlights the potential of SMT for noninvasive characterization of adult-type diffuse gliomas, with a potential to predict IDH status and tumor grade more accurately than traditional ADC metrics. SMT offers a promising addition to the current diagnostic toolkit, enabling more precise preoperative assessments and contributing to personalized treatment planning.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
NCNira Cedres
Nira Cedres
PDPatricia Diaz‐Galvan
Patricia Diaz‐Galvan
MNMilan Nemy
Milan Nemy
IAIris Alemany
Iris Alemany
MRMarta A. Rodriguez‐Hernandez
Marta A. Rodriguez‐Hernandez
DFDaniel Ferreira
Daniel Ferreira
Background: Neurodegeneration of cholinergic pathways may be present in individuals with subjective cognitive decline (SCD). However, variability between SCD individuals in the integrity of cholinergic pathways needs to be elucidated. Our objective was to determine characteristics of neurodegeneration of cholinergic pathways in different SCD subtypes (i.e. amnestic vs. non‐amnestic).Method: Individuals with amnestic SCD (n = 47), non‐amnestic SCD (n = 38), and healthy controls without cognitive complaints (HC; n = 20) from the GENIC database were included (all: >60 years old; 58% females). White matter integrity was estimated by mean diffusivity (MD) on diffusion tensor imaging (DTI) for cingulum and external cholinergic pathways. Both pathways were previously modelled using tractography on DTI. Memory performance was measured based on Visual reproduction WMS‐III and TAVEC (the Spanish version of the California Verbal Learning Test, CVLT). ANOVA and bivariate Pearson correlation were used for the statistical analysis.Result: Amnestic and non‐amnestic SCD groups were comparable to HC in the integrity of cholinergic WM pathways. Bivariate Pearson correlation analyses showed different patterns of association between the cholinergic pathways and cognition within each group. In amnestic‐SCD, worse WM integrity in both cholinergic pathways was associated with poorer immediate recall of visual information (external capsule: rxy = ‐0.42; p<0.05; cingulum: rxy = ‐0.34; p<0.05). In non‐amnestic‐SCD, worse WM integrity in both cholinergic pathways was associated with poorer delayed recall of verbal information (external capsule: rxy = ‐0.54; p<0.05; cingulum: rxy = ‐0.42; p<0.05); and worse WM integrity in the external capsule pathway was associated with poorer performance in immediate and delayed recall of visual information (rxy = ‐0.37; p<0.05 and rxy = ‐0.46; p<0.05). In HC, none of the cognitive outcomes was associated with the integrity of the cholinergic pathways.Conclusion: The cholinergic pathways were mainly associated with immediate recall in the amnestic SCD (i.e. acquisition of new information); whereas in non‐amnestic SCD the integrity of cholinergic pathways was associated with several subcomponents of memory performance (i.e. acquisition and recall of new information). Thus, SCD subtypes show unique patterns of associations between poorer integrity of the cholinergic system and memory performance.

1 January 2026 in Stroke
Verified
Journal Article
Closed access
MCMengfei Cai
Mengfei Cai
HLHao Li
Hao Li
MNMilan Nemy
Milan Nemy
MJMina A. Jacob
Mina A. Jacob
DNDavid G. Norris
David G. Norris
ATAnil M. Tuladhar
Anil M. Tuladhar
BACKGROUND: Cognitive decline and gait disturbance are often observed simultaneously in patients with small vessel disease (SVD), also known as motoric cognitive dysfunction. However, it remains unknown whether cholinergic system disruption contributes to motoric cognitive dysfunction. METHODS: In this cross-sectional, single-center study conducted in the Netherlands, we included 213 patients with SVD between 2020 and 2021, all of whom had multimodal magnetic resonance imaging scans, gait assessments using the 6-meter walk test, and cognitive test battery data available. Cholinergic cortical (through external capsule and cingulum) and thalamic projections (pedunculopontine nucleus to thalamus) were reconstructed using probabilistic tractography on diffusion images, followed by the quantification of the disruption in these tracts with diffusion metrics derived from neurite orientation dispersion and density imaging model. Conventional magnetic resonance imaging markers for SVD were assessed.Covariates, including neurite orientation dispersion and density imaging metrics in the white matter control mask and SVD markers, were adjusted in linear regression. RESULTS: A total of 213 patients with SVD were included, with a mean (SD) age of 74.6 (6.8) years, of whom 96 (45.1%) were women. Conventional SVD markers are differentially associated with disrupted cholinergic pathways, with white matter hyperintensities (WMH) being the main contributor (R² highest for neurite density index, 0.38). WMH within the external capsule cholinergic pathway is more strongly associated with the neurite orientation dispersion and density imaging metrics in this tract compared with total WMH volume or WMH outside cholinergic projections. In contrast, WMH within the cingulum pathway contributes less to neurite orientation dispersion and density imaging variability (R²=0.18–0.33 versus 0.22–0.38). Disruption in cholinergic cortical pathways was associated with concurrent decline in performance of cognition and gait (external capsule pathway cerebrospinal fluid isotropic volume fraction, β=−10.77; P =0.004; cingulum pathway cerebrospinal fluid isotropic volume fraction, β=−13.38; P =0.011), adjusted for the covariates. CONCLUSIONS: Taken together, our findings suggest that disruption in cholinergic cortical pathways attributable to SVD, rather than cholinergic thalamic pathways, contributes to the motoric cognitive dysfunction in patients with SVD.

16 June 2023 in Alzheimer's & Dementia
Verified
Journal Article
Open access
IAIris Alemany
Iris Alemany
MRMarta A. Rodriguez‐Hernandez
Marta A. Rodriguez‐Hernandez
PDPatricia Diaz‐Galvan
Patricia Diaz‐Galvan
MNMilan Nemy
Milan Nemy
EWEric Westman
Eric Westman
NCNira Cedres
Nira Cedres
Background: Subjective cognitive decline (SCD) is topic of mayor interest when identifying individuals at risk for future cognitive impairment and dementia. The degeneration of the cholinergic system is linked to the onset of cognitive symptoms in mild cognitive impairment (MCI) and dementia. Yet, it is uncertain whether the neurodegeneration of the cholinergic system is already present in SCD individuals. This review is the first to synthetize the available data on the association of SCD with multiple markers of degeneration in the cholinergic system.Method: Following the PRISMA guidelines, original articles focused on the association of SCD and the cholinergic system were extracted from three databases: Pubmed, WOS and Scopus, in November 2021. Two researchers reviewed the studies independently in a 2‐stepwise approach. The quality of the studies and risk of bias were assessed using FLC 3.0, that allows to systematically evaluate the studies and summarize them easily.Result: Among 119 studies found in our systematic search, 11 were included in the current review. Seven were cross‐sectional and 4 had a longitudinal design. Most of the studies operationalized SCD based on amnestic cognitive complaints (n = 9, 82%). The cholinergic system measures were based on neuroimaging markers for volume of the basal forebrain and/or functional connectivity, transcranial magnetic stimulation, or biofluid markers (i.e. cerebrospinal fluid (CSF) and plasma). The studies focused on association of SCD with basal brain atrophy, 75% reported reduce volumes in SCD; From those focused on functional connectivity of the cholinergic system, 33% reported poorer connectivity in SCD.Conclusion: Based on scientific evidence, neurodegeneration of the cholinergic system is already evident during SCD. Using multiple cholinergic biomarkers, degeneration of cholinergic system in SCD seems to occur with significant structural and functional degeneration of cholinergic nuclei in the basal forebrain and their connections with other brain areas. These findings have implications on identifying individuals with increased vulnerability to cognitive impairment and for targeting individuals that might benefit from cholinergic‐target treatments. Further research is needed to elucidate potential contributors to the cholinergic degeneration in SCD and its impact on cognition and clinical progression.